Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cobicistat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 known ✓ | P08684 | 20/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 7/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cobicistat SCHEMBL10201695 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| Cobicistat SCHEMBL2736053 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| Cobicistat SCHEMBL10201697 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| Cobicistat SCHEMBL16632480 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL18159507 | 0.98 | CYP3A4 (0.95) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL20674820 | 0.97 | CYP3A4 (0.94) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL23678770 | 0.97 | CYP3A4 (0.94) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL18583448 | 0.96 | CYP3A4 (0.93) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL15318473 | 0.95 | CYP3A4 (0.91) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 | |
| SCHEMBL10129122 | 0.95 | CYP3A4 (0.91) | CYP3A4CYP2D6CYP2C9CYP2C19ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3155 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| WO-2026102345-A1 | METHODS OF ADMINISTERING THE VOLTAGE-GATED POTASSIUM CHANNEL OPENER AZETUKALNER | XENON PHARMACEUTICALS INC. (CA) | 2026-05-15 | — | — | WO | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| EP-4735033-A2 | MRNA-ENCODED TAT WITH ATTENUATED CYTOTOXICITY FOR HIV AND SIV LATENCY REVERSAL | The Trustees of the University of Pennsylvania (US) | 2026-05-06 | — | — | EP | claimed |
| US-12611453-B2 | Method of inducing an HIV-1-specific immune response using a chimpanzee adenovirus vector encoding an hivacat t-cell immunogen and TLR7 agonist | GILEAD SCIENCES, INC. (US) | 2026-04-28 | — | — | US | claimed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | claimed |
| EP-4724062-A2 | COMPOSITIONS AND METHODS FOR INCREASING EXPOSURE OF R(-)-MDA | EmpathBio, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-12594269-B2 | Method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome P450 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-04-07 | — | — | US | claimed |
| EP-4714452-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | Gilead Sciences, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-3963087-A1 | IDENTIFICATION AND ANALYSIS OF MICROBIAL SAMPLES BY RAPID INCUBATION AND NUCLEIC ACID ENRICHMENT | Illumina Inc (US) | 2022-03-09 | — | — | EP | claimed |
| US-20220062243-A1 | P14-Kinase Inhibitors with Anti-Cancer Activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-03-03 | — | — | US | claimed |
| US-20220062293-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2022-03-03 | — | — | US | claimed |
| EP-3960735-A1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | Gilead Sciences, Inc. (US) | 2022-03-02 | — | — | EP | claimed |
| US-20220054495-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DELIVERY OF ANTIVIRAL AGENTS | Poviva Corp. (US) | 2022-02-24 | — | — | US | claimed |
| WO-2022040435-A1 | NANODRUGS FOR TARGETED DRUG DELIVERY AND USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-24 | — | — | WO | claimed |
| WO-2022031761-A2 | TARGETED DELIVERY OF THERAPEUTIC AGENTS | SEPELO THERAPEUTICS, LLC (US) | 2022-02-10 | — | — | WO | claimed |
| CN-114025751-A | Compositions and methods for treating hepatitis b virus infection | 安徽荣航生物科技发展有限责任公司 | 2022-02-08 | — | — | CN | claimed |
| WO-2022026622-A2 | TREATMENT OF VIRAL DISEASES | CYTOCOM INC. (US) | 2022-02-03 | — | — | WO | claimed |
| US-20220023287-A1 | TREATMENT OF HEPATITIS DELTA VIRUS INFECTION | EIGER BIOPHARMACEUTICALS, INC. (US) | 2022-01-27 | — | — | US | claimed |